Brief: Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
01/10/2026 07:42
BRIEF-Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study Oct 1 (Reuters) - Pfizer Inc. PFE.N:
PFIZER'S TILREKIMIG SHOWS SIGNIFICANT SKIN CLEARANCE IN PHASE 2 ATOPIC DERMATITIS STUDY
PFIZER - PHASE 2 STUDY MEETS PRIMARY ENDPOINT WITH SIGNIFICANT EASI-75 IMPROVEMENT AT WEEK 16
PFIZER - TILREKIMIG WELL-TOLERATED WITH TEAE RATES COMPARABLE TO PLACEBO
PFIZER - 62.5% OF PATIENTS ON TILREKIMIG 450 MG Q2W ACHIEVE EASI-75 VERSUS 19.9% PLACEBO
PFIZER - NO SERIOUS ADVERSE EVENTS RELATED TO TILREKIMIG IN PHASE 2 STUDY
PFIZER - STAGE 2: UP TO 61% OF PATIENTS ON TILREKIMIG ACHIEVE EASI-75 VERSUS 9.1% PLACEBO
Source text: ID:nBw2fsQ7Va
Further company coverage: PFE.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pfizer
See all newsBrief: Enanta Pharmaceuticals In Patent Infringement Action Against Pfizer
Brief: Edison Scientific Announces Agreement With Pfizer To Accelerate Research And Development
Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge (updated)
Corrected: Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Brief: Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma